Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical)

伊匹木单抗生物类似药（博威生物医药/双鹭药业）

Report date: 2022/05/07 13:53:49

Base Information

Drug NameIpilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical)
Drug Alias NameMV-049
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Sl Pharmaceutical Co LtdMab-Venture Biopharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Sl Pharmaceutical Co LtdMab-Venture Biopharm Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A